An environmental risk assessment for oseltamivir (Tamiflu) for sewage works and surface waters under seasonal-influenza- and pandemic-use conditions.

In the event of an influenza pandemic, anti-viral medications such as oseltamivir (Tamiflu) are expected to be used in high amounts over a duration of several weeks. Oseltamivir has been predicted to reach high concentrations in surface waters and sewage works. New oseltamivir environmental fate and toxicity studies permit an environmental risk assessment (ERA) under seasonal- and pandemic-use scenarios. The environmental fate data for sewage works (no removal), surface waters (no significant degradation), and water/sediment systems (>50% primary degradation in 100 days) were used for the derivation of new predicted environmental concentrations (PECs) for western Europe and the River Lee catchment in the UK. Existing worst-case PECs for western Europe, the River Lee catchment in the UK and the Lower Colorado basin in the USA under pandemic conditions (< or =98.1 microg/L for surface waters, < or =348 microg/L for sewage works) were also considered for the ERA. PECs were compared with predicted no-effect concentrations (PNECs) based on new chronic ecotoxicity data (no observed effect concentration for algae, daphnia, and fish > or =1 mg/L). Based on all PEC/PNEC risk ratios, no significant risk is evident to surface waters or sewage works during both regular seasonal-use and high pandemic-use of oseltamivir.

[1]  P. Grenni,et al.  Degradation of the antiviral drug oseltamivir carboxylate in surface water samples , 2007 .

[2]  Andrew C. Singer,et al.  Potential Risks Associated with the Proposed Widespread Use of Tamiflu , 2006, Environmental health perspectives.

[3]  B. Escher,et al.  Screening method for ecotoxicological hazard assessment of 42 pharmaceuticals considering human metabolism and excretory routes. , 2007, Environmental science & technology.

[4]  W. von Tümpling,et al.  The environmental fate of the antiviral drug oseltamivir carboxylate in different waters. , 2008, The Science of the total environment.

[5]  Mark von Itzstein,et al.  The war against influenza: discovery and development of sialidase inhibitors. , 2007, Nature reviews. Drug discovery.

[6]  Jürg Oliver Straub,et al.  Meeting Report: Risk Assessment of Tamiflu Use Under Pandemic Conditions , 2008, Environmental health perspectives.

[7]  Mark von Itzstein,et al.  The war against influenza: discovery and development of sialidase inhibitors , 2007, Nature Reviews Drug Discovery.

[8]  Mats Tysklind,et al.  Antiviral Oseltamivir Is not Removed or Degraded in Normal Sewage Water Treatment: Implications for Development of Resistance by Influenza A Virus , 2007, PloS one.

[9]  K. Kümmerer Pharmaceuticals in the Environment , 2001 .

[10]  Peter Shanahan,et al.  Screening analysis of human pharmaceutical compounds in U.S. surface waters. , 2004, Environmental science & technology.

[11]  Keiji Fukuda,et al.  WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus , 2006, The Lancet Infectious Diseases.